ArticleFrontiers in medicine2026
Clinical features, management, and outcomes of pulmonary mucormycosis: a decade-long retrospective study from a single center in central China.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary mucormycosis is a life-threatening invasive fungal infection with challenging, often delayed diagnosis and high mortality. This study aims to elucidate the clinical characteristics, diagnostic and therapeutic approaches, and outcomes of pulmonary mucormycosis. Methods: This retrospective study enrolled inpatients diagnosed with pulmonary mucormycosis from January 2015 to May 2025. Clinical data were systematically collected and analyzed. Results: A total of 16 patients with pulmonary mucormycosis were included in the study. The mean age of the cohort was 52.50 ± 15.02 years, with a male predominance of 68.75%. Diabetes mellitus was identified as the most prevalent underlying condition, affecting 81.25% of patients. The most common clinical symptoms included cough (100%), expectoration (81.25%), fever (68.75%), chest tightness (68.75%), hemoptysis (50%), and chest pain (50%). Common imaging findings comprised nodules <3 cm (87.50%), consolidation (87.50%), ground-glass opacities (75.00%), halo sign (62.50%), and pleural effusion (50.00%). Of the 16 patients, 68.75% exhibited bronchial involvement. Twelve patients were confirmed by histopathology, and one by culture of sterile pleural fluid; the remaining three were classified as probable cases based on clinical and radiological findings, combined with detection of mucorales by mNGS or from non-sterile specimen cultures. The most frequently identified pathogen was Rhizopus microsporus. Systemic antifungal therapy was administered to 13 patients (81.25%), primarily involving a combination of amphotericin B formulations and azoles. Seventy-five percent of patients underwent bronchoscopic debridement or surgical intervention. The 12-month survival rate was 81.25%, with three patients succumbing to sepsis, massive hemoptysis, or respiratory failure, two of whom had extrapulmonary involvement. In this series, favorable outcomes were observed in patients who received combination therapy, particularly bronchoscopic debridement coupled with antifungal medication. Conclusion: Pulmonary mucormycosis is highly lethal, frequently associated with bronchial involvement. Bronchoscopy plays a crucial role in both diagnosis and treatment. Combined surgical/bronchoscopic intervention with systemic and local antifungal therapy may contribute to favorable outcomes in this series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.